MedTrace Logo

Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device

NCT04239105 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-01-23

No results posted yet for this study

Summary

Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In this project, the investigators will explore a novel detection technology of circulating tumor cells in breast cancer using novel Microfluidic and Raman Spectrum Device. The primary objective is to demonstrate that the CTC assay counts technology can distinguish between healthy subjects and malignant breast cancer subjects. The secondary objective is to demonstrate that the CTCs detection technology can evaluate the efficacy of chemotherapy and neoadjuvant chemotherapy, as well as dynamic treatment monitoring and prognosis evaluation.

Conditions

  • Breast Neoplasms
  • Circulating Tumor Cells

Interventions

DEVICE

Microfluidic and Raman spectrum

Detection of Circulating Tumor Cells

Sponsors & Collaborators

  • Xidian University

    collaborator OTHER

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Shifang Yuan, Ph.D · Xijing Hospital

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2021-07-31
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04239105 on ClinicalTrials.gov